Amgen Inc.

The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.

247wallst.com - 2026-07-17 11:05:33

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-16 13:11:08

Amgen (AMGN) closed the most recent trading day at $355.25, moving 1.44% from the previous trading session.

zacks.com - 2026-07-14 18:51:16

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-07-14 12:40:26

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.

247wallst.com - 2026-07-14 11:51:03

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com - 2026-07-13 10:01:23

On July 13, 2026, we present a detailed DCF analysis for Amgen Inc (AMGN), a company that has shown significant price performance over the past year with a 24.6

gurufocus.com - 2026-07-13 07:30:00

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

247wallst.com - 2026-07-09 11:35:25

Near-term headwinds could sink the stock, but there is more to the story.

fool.com - 2026-07-07 14:45:00

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

247wallst.com - 2026-07-07 12:30:17

Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.

zacks.com - 2026-07-06 19:01:15

Broadcom's Apple deal and AMD's self-driving ambitions powered the Nasdaq higher on Monday while the Dow spun its wheels.

fool.com - 2026-07-06 14:29:06

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-07-06 13:01:13

A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind ‌move by a U.S. state.

reuters.com - 2026-07-01 16:47:34

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

zacks.com - 2026-07-01 10:05:15

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

zacks.com - 2026-07-01 09:16:09

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-06-30 10:01:19

Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its marketing segments in the first quarter.

fool.com - 2026-06-30 06:05:00

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen's ​rare-disease drug, citing concerns that patient outcome data were altered and ‌that some researchers had been unblinded.

reuters.com - 2026-06-29 16:46:26

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).

benzinga.com - 2026-06-29 09:24:47

The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.

wsj.com - 2026-06-26 08:26:00

The European Medicines Agency on ‌Friday recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug, ​Tavneos, citing a lack of ​benefits that outweigh its risks.

reuters.com - 2026-06-26 07:10:11

In the most recent trading session, Amgen (AMGN) closed at $351.93, indicating a +1.42% shift from the previous trading day.

zacks.com - 2026-06-24 18:50:26

Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.

fool.com - 2026-06-23 19:33:07

AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.

zacks.com - 2026-06-23 10:51:39

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

fool.com - 2026-06-23 02:45:00

Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor-treating electrical fields.

fool.com - 2026-06-19 12:50:34

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com - 2026-06-19 10:01:19

The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.

zacks.com - 2026-06-17 18:50:31

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-06-17 10:50:21

On June 15, 2026, we delve into the DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance over the past year, with a 23.1% increa

gurufocus.com - 2026-06-15 07:34:00

The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 14, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation.

prnewswire.com - 2026-06-14 20:01:00

Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.

cnbc.com - 2026-06-13 08:00:01

Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it seeks to ​prove its benefits following the U.S. health regulator's ‌proposal to withdraw it from the market.

reuters.com - 2026-06-11 19:28:49

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.

zacks.com - 2026-06-10 18:50:25

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

zacks.com - 2026-06-10 13:01:19

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

zacks.com - 2026-06-10 09:32:21

Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 12:52:11

Amgen NASDAQ: AMGN executives said the company's first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity.

marketbeat.com - 2026-06-09 11:07:00

More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.

forbes.com - 2026-06-09 09:20:23

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com - 2026-06-08 10:01:27

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS PR Newsw

gurufocus.com - 2026-06-07 17:00:00

VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.

prnewswire.com - 2026-06-07 16:45:00

This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500. Its growth rate has been better than that of many dividend-focused funds.

fool.com - 2026-06-06 18:30:00

Explore the exciting world of Amgen (AMGN +1.15%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

fool.com - 2026-06-05 19:00:00

Amgen Inc. is upgraded to a cautious Buy, reflecting improved fundamentals, a diversified pipeline, and a decent risk/reward profile despite recent underperformance versus the S&P. Key growth drivers include Imdelltra, Uplizna, Tepezza, Repatha, and the promising but unproven Maritide, offsetting declines from legacy drugs like Prolia. AMGN's robust R&D pipeline, margin expansion, and capital investments are positioning the company for sustained long-term growth, though high debt and capex warrant monitoring.

seekingalpha.com - 2026-06-05 08:00:00

Amgen NASDAQ: AMGN executives used a Jefferies investor conference appearance to emphasize the company's first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide.

marketbeat.com - 2026-06-05 01:03:24

THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m.

prnewswire.com - 2026-06-04 16:01:00